According to the results announced at the 2018 ASCO annual meeting, the CDK4/6 inhibitors pabociclib (Ibrance) and cetuximab (Erbitux) combined treatment of platinum-resistant and HPV-independent recurrent/metastatic head and neck The overall response rate for patients with squamous cell carcinoma (HNSCC) is 39%. In a non-randomized, 3-arm, phase II trial (NCT02101034), the results of a group of studies have a median progression-free survival (PFS) of 5.4 months, a median overall survival (OS) of 9.5 months, and a 1-year OS The rate is 35%.
In this study, 30 patients with HNSCC unrelated to HPV progressed after platinum-based therapy for relapsed/metastatic disease and participated in the trial. Patients who had previously received cetuximab for relapse and HPV-related oropharyngeal cancer were not eligible. Patients received palbociclib from day 1 to day 21, 125 mg daily; cetuximab, with a starting dose of 400 mg/m 2 and then 250 mg/m 2 per week for a period of 28 days until the disease progressed or withdrew the study. The researchers performed imaging examinations before treatment and after every 2 cycles.
كان متوسط عمر المرضى 67 عامًا، وكانت مواقع الورم هي تجويف الفم (47٪)، والحنجرة (27٪)، والبلعوم الفموي (13٪). 20% من المرضى لديهم نقائل إقليمية محلية، 27% لديهم نقائل بعيدة، و53% لديهم كليهما. تلقى خمسة عشر (50٪) من المرضى علاجين ≥.
من بين 28 مريضًا قابلين للتقييم ، كان لدى 11 (39٪) استجابات للورم ، بما في ذلك 3 (11٪) استجابات كاملة و 8 (29٪) استجابات جزئية. أربعة عشر (50٪) مريضا لديهم مرض مستقر ، 3 (11٪) مرضى لديهم تقدم ، و 70٪ لديهم آفات أورام أقل.
Researcher Dr. Adkins said that Palbociclib and cetuximab have strong antitumor activity in platinum-resistant HPV-independent head and neck cancer, and biologically targeted therapy for HPV-independent head and neck cancer is an effective treatment strategy. . We look forward to the better results of the follow-up research.
